Api list_1.10.2012 final 1.10.2012 print
Active Pharmaceutical Ingredients*
# US DMF + CTD filing under process * WHO APIMF CEP / COS
*The Technical and Physical manufacturing capabilities exist with us for the above APIs and their intermediates. However these products will be offered onlyto the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing productsfor regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Calyx offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction.
Products under patent offered only for exempted research, clinical and development purposes. Only non-infringing products and processes are offered, subject to patent status verification by client.
Calyx Chemicals and Pharmaceuticals Limited
Reg. Office: Unit No.110, Marwah’s Complex, Krishanlal Marwah Marg, Off. Saki Vihar Road,
Andheri (East), Mumbai – 400072, Maharashtra, India.
Tel: +91-22-28571191 Fax: +91-22-66466416
USA Contact: 11728 E. Imperial Highway, Norwalk, CA 90650, Tel - 213-291-7773
Email: email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, www.calyxindia.com
"Calyx Chemicals and Pharmaceuticals Limited (the “Company”
) is proposing to make, subject to receipt of requisite approvals, market conditions and other considerations, an Initial
Public Offering of its equity shares (the “IPO"
) and has filed the Draft Red Herring Prospectus (the “DRHP”
) with the Securities and Exchange Board of India (“SEBI”
). The DRHP is
available on the website of SEBI at www.sebi.gov.in
, the website of the BRLMs, i.e. PL Capital Markets Private Limited at www.plindia.com
and YES Bank Limited at www.yesbank.in
and is also available on the website of the Company at www.calyx-pharma.com
. Potential investors should note that investment in equity shares involves a degree of risk. For details,
please refer to the DRHP, including the section titled “Risk Factors” of the DRHP. This publicity material does not constitute an offer of securities in any jurisdiction, including the United
States of America (“USA”
). Securities may not be offered or sold in the USA without registration under the U.S. Securities Act of 1933 as amended, or an exemption therefrom. The
Company has not and does not intend to offer any securities to the public in the USA.
Currículum Resumido Dra. Marcela Redruello Títulos Médico, otorgado por la Universidad de Buenos Aires el 22 de diciembre de 1989. Títulos de posgrado - Médico Especialista en Cardiología, recibida el 21 de diciembre de 1993 Otorgado por la Universidad Católica Argentina - Médico Especialista en Medicina Nuclear. Recibida en noviembre de 1998. Otorgado por la Universidad d
Y A-T-IL ENCORE UNE VIE SEXUELLE APRÈS TRAITEMENT POUR CANCER DE LA PROSTATE ? B. TomBal 1, R.J. opsomeR 1, l. RenaRd 2 Résumé Le cancer de la prostate est le cancer le plus fréquent de l’homme âgé de plus de 50 ans. Malgré que plus de la moitié des cancers dia- Cliniques universitaires Saint Luc gnostiqués aujourd’hui soient peu agressifs, la p